Protein C levels help predict severity of illness and risk of death in ICU patients

NewsGuard 100/100 Score

A simple laboratory test to measure protein C - a natural anti-blood-clotting substance that also reflects the level of inflammation in the body - may offer a useful new indicator of the severity of illness and risk of death among critically ill patients.

The July issue of the journal Anesthesiology features the new study by Dr. Frank Brunkhorst and colleagues of Friedrich Schiller University in Jena, Germany. "Protein C may be a new target for therapy for patients with non-infectious-induced organ failure/dysfunction in the intensive care unit," said Dr. Brunkhorst. "The possibility to measure protein C levels at the bedside in critically ill patients—without time-delay by the central lab—would be a great step forward in assessing prognosis, and may influence clinical decision making at an early stage of the evolution of organ dysfunction."

The researchers analyzed the relationship between protein C and indicators of organ failure in 312 patients admitted to the ICU after major surgery. Changes in protein C levels over time were analyzed, along with their ability to predict the patients' risk of death.

About half of the patients had lower-than-normal protein C levels—reflecting an increased risk of abnormal blood clotting—when they first arrived at the ICU. Protein C decreased further over the next three to four days before returning to normal by about two weeks.

Lower protein C concentrations were correlated with increased severity of sepsis and with greater organ dysfunction. In contrast, patients with less-severe illness—based on standard severity scores—had higher protein C levels.

Overall, 15 percent of patients died. Particularly during their first four days in the ICU, this group had lower protein C levels than patients who survived.

With adjustment for other factors, the risk of death was four times higher for patients whose minimum protein C level was below a certain cutoff point. Protein C was the strongest predictor of risk of death—even stronger than the standard severity scores.

Previous studies have noted low protein C levels in critically ill patients, but most have focused on patients with sepsis. Gaining a better understanding of the factors associated with protein C might help ICU specialists to identify patients at high risk of severe illness and death—and possibly provide an opportunity for treatments to lower those risks.

The new study—the largest so far to look at protein C levels in critically ill patients—suggests that protein C may be a valuable indicator of severity of illness and risk of death in the ICU. "Severe sepsis is responsible for 750,000 deaths a year in the U.S.," commented Dr. Michael A. Gropper of University of California, San Francisco, author of an editorial accompanying the new study. "The ability to identify these patients and treat them early will significantly improve their chance of survival. This study is important because it identifies a strategy to easily identify patients with severe sepsis and multisystem organ failure."

The results add to previous studies suggesting that treatments targeting the protein C pathway might benefit critically ill patients. Although much more research will be needed, treatment with recombinant protein C could offer a new way of interrupting the progression to sepsis and organ failure in high-risk patients. In his editorial, Dr. Gropper concludes, "We await further studies of the coagulation pathway in the hopes of new therapies for this devastating syndrome."

For additional information on this study, go to: http://www.anesthesiology.org

Founded in 1905, the American Society of Anesthesiologists is an educational, research and scientific association with 41,000 members organized to raise and maintain the standards of the medical practice of anesthesiology and improve the care of the patient.

http://www.asahq.org 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
An ActRIIA fusion protein got FDA approved for PAH treatment